Journal News

From the journals: JBC

Ken Farabaugh
Feb. 8, 2023

The timing of lipid metabolism. Modifying actin assembly dynamics. How Lyme disease evades the immune system. Read about papers on these topics recently published in the Journal of Biological Chemistry.

 

The timing of lipid metabolism

Pixabay

The liver is a hub of lipid metabolism, with hepatocytes regulating uptake, esterification, oxidation and secretion of fatty acids and lipid droplet storage. Disruption of the molecular clock (a transcription- and translation-based feedback loop) or metabolic/redox oscillator (which drives oxidation–reduction cycles of reactive oxygen species and lipids), two circadian timing systems that regulate behavioral and physiological processes according to a 24-hour light/dark cycle, can cause metabolic imbalances leading to fatty liver, dyslipidemia, glucose intolerance and an increased risk of cancer. However, little is known about how disruption of the intrinsic clock mechanistically alters metabolic pathways.

In a recent paper published in the Journal of Biological Chemistry, Natalia Monjes and colleagues at the Universidad Nacional de Córdoba in Argentina describe their study that found that disruption of the Bmal1 gene, a key component of the molecular clock, dampened temporal patterns in lipid metabolism of tumor cells compared to control cells. This dampening of lipid processes was accompanied by severe decreases in endogenous triglyceride levels, lipid droplet accumulation and reactive oxygen species content. The authors also observed an increase in lactate levels, which could indicate a Warburg effect–like hypermetabolic state.

These results not only confirm the phenomenon of serum-synchronized molecular cycling in HepG2 cells but also indicate an effect of this cycling on lipid biosynthesis and, in particular, on the ratios of specific phospholipids. These findings also highlight a metabolic susceptibility of tumor cells to circadian disturbance, which could be used to improve chronotherapeutic efficacy.

Modifying actin assembly dynamics

The assembly and disassembly of the actin network is crucial for regulating many cellular processes, including cell motility, cell division and intracellular transport. The diversity of these actin networks is the result of a multitude of remodeling proteins and posttranslational modifications, which can fine-tune actin fiber nucleation and elongation. However, researchers do not know yet how N-terminal posttranslational modifications such as acetylation and arginylation, which may constitute only a small percentage of actin at the leading edge of cells and filopodia, can affect the properties of actin.

Samantha Chin at Washington University in St. Louis and an international team used a method known as “pick-ya-actin” to produce pure populations of acetylated and arginylated actin (Ac-actin and R-actin, respectively) to compare their contributions directly to actin network dynamics, and they describe this work in a recent paper in the Journal of Biological Chemistry. Using pyrene-bound actin (which fluoresces upon polymerization) and total internal reflection fluorescence microscopy, they showed that Ac-actin exhibits higher spontaneous nucleation than R-actin, and that R-actin exhibits reduced elongation and branching compared to Ac-actin. The authors found no difference in cofilin-mediated severing of Ac-actin and R-actin strands, suggesting the effects of these modifications are primarily on assembly rather than disassembly kinetics.

These data begin to highlight an emerging role for N-terminal acetylation and arginylation of actin in the regulation of actin networks.

How Lyme disease evades the immune system

The complement cascade is a primary arm of the innate immune system, consisting of sequential protein cleavages that result in microbial death. However, some bacteria, such as Borreliella burgdoferi, which causes Lyme disease, have evolved outer surface-localized lipoproteins that help them evade complement-mediated attack. Researchers have identified two such proteins, termed ElpB and ElpQ, but have yet to understand fully the mechanism by which they inhibit the complement cascade.

In a follow-up study by Ryan Garrigues of East Carolina University and colleagues, published in the Journal of Biological Chemistry, the authors used multiple binding assays to show that the C-terminal domains of these Elp proteins were able to bind to complement protein C1s and block subsequent cleavage of the next sequential complement protein, C4. Furthermore, they found that this binding did not compete with C4 at the enzyme’s active site but rather occurred at an activation-induced binding site called an exosite.

Based on these results, the authors propose a model in which ElpB and ElpQ exploit activation-induced conformational changes in C1s that normally would promote C4 cleavage to prevent this reaction and thereby inhibit the complement cascade. This study shows a novel molecular mechanism employed by Lyme disease spirochetes to evade immune attack.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ken Farabaugh

Ken Farabaugh is a former ASBMB science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Differences in pili structure modulate bacterial behavior
Journal News

Differences in pili structure modulate bacterial behavior

April 14, 2026

Researchers demonstrate how small changes in the structure of hair-like protein appendages can affect the behavior of Acinetobacter bacteria.

Cholesterol regulatory genes predict liver transplant outcomes
Journal News

Cholesterol regulatory genes predict liver transplant outcomes

April 10, 2026

Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Journal News

Lipid signatures for a rare neurological disorder

April 10, 2026

Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Journal News

Disease-linked mutations disrupt protein phase behavior

April 9, 2026

Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Journal News

The dual role of asprosin in chronic fatty liver disease

April 8, 2026

Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Journal News

Novel inhibitor targets RAS-driven cancers

April 7, 2026

Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.